Augustine Therapeutics lands $85m to advance HDAC6 inhibitors for chronic diseases

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Startup boasts pipeline of candidates targeting neuromuscular, neurodegenerative and cardio-metabolic diseases.

Belgian biotech Augustine Therapeutics has raised $84.8 million in an oversubscribed Series A financing round to advance its pipeline of HDAC6 inhibitors targeting neurodegenerative and cardio-metabolic diseases.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3520

Augustine Therapeutics

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Augustine Therapeutics is a clinical-stage biopharmaceutical company developing selective histone deacetylase 6 (HDAC6) inhibitors for neuromuscular, neurodegenerative, and cardiometabolic diseases. The company's proprietary small-molecule platform targets HDAC6 with a novel non-hydroxamate chemotype designed to avoid off-target toxicities while maintaining therapeutic efficacy. Augustine's lead candidate, AGT-100216, entered Phase I clinical trials in 2025 for Charcot-Marie-Tooth disease, with additional programs in development for conditions including amyotrophic lateral sclerosis, Alzheimer's disease, and heart failure with preserved ejection fraction. The company aims to address unmet medical needs in chronic neurological and metabolic disorders by modulating a validated but previously challenging drug target.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE